What are the research applications of BPC-157?

Aplicacoes de Pesquisa BPC-157 demonstra pleiotropic effects across multiplos(as) experimental paradigms, with unusually broad tissue coverage for a single peptide: Gastrointestinal Healing — Anti-ulcer peptidergic agent eficaz against IBD, ulcerative colitis, NSAID-induziu lesions, and complex fistulas. Phase II human data available (n=53, ulcerative colitis).[6] Musculoskeletal Regeneration — Accelerated healing of transected/detached tendons (Achilles, quadriceps)

How does BPC-157 work in research models?

Published in-vitro and pre-clinical work focuses on its interaction with the nitric-oxide system, growth-factor expression (notably VEGF and FGF), and angiogenic signaling pathways relevant to vascular and connective-tissue research.

What is the half-life of BPC-157 in research literature?

Reported terminal half-life in pre-clinical studies is short — generally measured in minutes when administered intravenously — though local-tissue persistence has been reported to be longer in lyophilized research preparations.

What purity is the BPC-157 sold by Pure U.S. Peptides tested at?

Every lot of BPC-157 10mg ships at greater than 99% purity verified by reversed-phase HPLC and confirmed by mass spectrometry through an independent ISO 17025 third-party laboratory.

Does BPC-157 ship with a Certificate of Analysis (COA)?

Yes. Each vial is matched to a lot-specific COA showing HPLC purity, mass-spec identity confirmation, residual-solvent screen, and endotoxin testing. The COA is downloadable from the product page after lot assignment.

How should BPC-157 be stored and handled in the lab?

Lyophilized BPC-157 is stable at -20°C protected from light. After reconstitution with bacteriostatic water it is generally stored at 2-8°C. Avoid repeated freeze-thaw cycles on reconstituted material.

How is BPC-157 shipped?

Orders ship the same business day from a temperature-controlled U.S. facility via tracked carrier. Lyophilized peptide is stable in transit at ambient temperatures for the shipping window.

Is BPC-157 third-party tested?

Yes — every production lot is independently tested by an ISO 17025 lab for HPLC purity, mass-spec identity, and endotoxin level before release. Results are recorded against the lot number on the COA.

What is the difference between BPC-157 and TB-500?

BPC-157 and TB-500 are both research peptides commonly studied in tissue-recovery models, but they have distinct sequences, mechanisms, and target pathways. BPC-157 originates from gastric juice protein; TB-500 is a fragment of thymosin β4 with actin-binding activity.

How can researchers verify the quality of BPC-157 from Pure U.S. Peptides?

Researchers can cross-reference the lot-specific COA, request the third-party HPLC/MS chromatograms, and contact the lab support team to confirm batch traceability against the certificate.

Where can researchers find published studies on BPC-157?

PubMed indexes a body of pre-clinical work on BPC-157 spanning gastrointestinal, vascular, and musculoskeletal research models. The product research page links to peer-reviewed citations with PubMed identifiers.

Is BPC-157 a stable peptide in solution?

BPC-157 is reported in pre-clinical literature to demonstrate notable stability in gastric juice — a property unusual among peptides — but reconstituted material should still be stored cold and used within recommended windows.

✨99% de Pureza

BPC-157

Name: BPC-157
Brand: Pure U.S. Peptides
SKU: 72
Price: 65.00 USD
Availability: InStock

Em Estoque10mg

Selecione Tamanho ou Peso

10mg 20mg

$65.00

Em Estoque e Pronto para Envio dos EUA

Frete GRATIS em pedidos acima de US$200

AMERICANEXPRESSDISCOVERSSL

Checkout seguro via processador de pagamento criptografado

Testado nos EUAe Verificado

HPLCTestado

Espec. de MassaVerificado

TerceirosCOA

QualidadeGarantia

🚚Frete GRATIS em pedidos acima de US$200

⚡Envio no mesmo dia se pedido antes das 14h EST (Seg-Sex)

📦Entrega estimada: 2-3 dias uteis via USPS Priority Mail

Apenas para Uso em Pesquisa

Estes produtos sao destinados exclusivamente a pesquisa laboratorial e nao se destinam ao uso medico. Nao sao aprovados pela FDA para diagnosticar, tratar, curar ou prevenir qualquer doenca. Ao adquirir, voce certifica que os produtos serao utilizados exclusivamente para pesquisa e nao para consumo humano ou animal.

⚠️Estritamente para pesquisa laboratorial in vitro.

SKU: 72

Resumo da Pesquisa

30 Citacoes PubMed

Visao Geral BPC-157 (Body Protection Compound-157, Bepecin, PL 14736) e um(a) sintetico(a) pentadecapeptide composto(a) por 15 aminoacidos (GEPPPGKPADDAGLV), derivado(a) de a partial sequence of a larger Body Protection Compound protein naturally encontrado(a) em human gastric juice.[1][2] Originally isolado(a) by Dr. Predrag Sikiric's grupo de pesquisa no(a) University of Zagreb in 1993, BPC-157 is one do(a) a maioria extensively studied cytoprotective peptides in preclinical literature. It demonstra pleiotropic effects across gastrointestinal, musculoskeletal, neurological, and vascular models.[8] A key distinguishing feature is its exceptional stability — BPC-157 resists enzymatic degradacao in human gastric juice for over 24 hours, is eficaz via multiplos(as) routes (oral, parenteral, topical) sem requiring a carrier molecule, and has shown no lethal dose (LD1) in toxicology studies.[3][9] The U.S. FDA placed BPC-157 no(a) Categoria 2 Substancia Farmaceutica a Granels list in September 2023, citing potential immunogenicity risks and insufficient safety data for human manipulacao.[4] WADA explicitly banned BPC-157...

Ultima Revisao: May 2026Escrito por EspecialistasFontes Revisadas por Pares

BPC-157 — Dados de Pesquisa em Resumo

Propriedade	Valor
Citacoes PubMed Referenciadas	30
Pesquisadores Colaboradores	3
Condicoes de Armazenamento	BPC-157 é excepcionalmente estável à temperatura ambiente.
Padrao de Pureza	≥99% (HPLC verified, 3rd-party COA)
Apenas para Uso em Pesquisa	Nao destinado ao consumo humano. Apenas para uso em pesquisa.

Compare BPC-157 com Outros Peptideos

BPC-157 vs TB-500 BPC-157 vs GHK-Cu

1.Visao Geral 2.Mecanismo de Acao 3.Aplicacoes de Pesquisa 4.Caracteristicas Bioquimicas 5.Resumo da Pesquisa Pre-clinica

6.Autores e Atribuicao 7.Citacoes Referenciadas 8.Aviso de Uso em Pesquisa 9.Certificado de Analise 10.Armazenamento e Manuseio

Visao Geral

BPC-157 (Body Protection Compound-157, Bepecin, PL 14736) e um(a) sintetico(a) pentadecapeptide composto(a) por 15 aminoacidos (GEPPPGKPADDAGLV), derivado(a) de a partial sequence of a larger Body Protection Compound protein naturally encontrado(a) em human gastric juice.[1][2]

Originally isolado(a) by Dr. Predrag Sikiric's grupo de pesquisa no(a) University of Zagreb in 1993, BPC-157 is one do(a) a maioria extensively studied cytoprotective peptides in preclinical literature. It demonstra pleiotropic effects across gastrointestinal, musculoskeletal, neurological, and vascular models.[8]

A key distinguishing feature is its exceptional stability — BPC-157 resists enzymatic degradacao in human gastric juice for over 24 hours, is eficaz via multiplos(as) routes (oral, parenteral, topical) sem requiring a carrier molecule, and has shown no lethal dose (LD1) in toxicology studies.[3][9]

The U.S. FDA placed BPC-157 no(a) Categoria 2 Substancia Farmaceutica a Granels list in September 2023, citing potential immunogenicity risks and insufficient safety data for human manipulacao.[4] WADA explicitly banned BPC-157 under S0 (Non-approved Substances) eficaz January 1, 2022.[5]

Mecanismo de Acao

VEGFR2 Activation (Primary Target)

BPC-157 liga-se a and ativa vascular endothelial fator de crescimento receptor 2 (VEGFR2) on celulas endoteliais. Diferentemente de standard ligands, BPC-157 promove VEGFR2 internalizacao — um(a) critico(a) step in activating downstream repair pathways.[7][10]

Src Family Kinase Activation

A 2025 study proposes que BPC-157 adopts a polyproline II helix structure que engages the SH3 domains of Src family kinases (c-Src, Yes, Fyn), relieving autoinibicao and acting como um(a) intracellular "switch" for signal transduction.[11]

VEGFR2-Akt-eNOS Cascade

Upon VEGFR2 binding, BPC-157 desencadeia fosforilacao of Akt (Protein Kinase B), que ativa endothelial nitric oxide synthase (eNOS), producing nitric oxide (NO) — essencial para angiogenese and vascular repair.[7]

Src-Caveolin-1-eNOS Pathway

BPC-157 promove fosforilacao of Src and Caveolin-1 (Cav-1). Under normal conditions, Cav-1 inibe eNOS — BPC-157 disrupts this inhibitory complex, enhancing NO production.[10]

FAK-Paxillin Pathway

In tendon fibroblastos, BPC-157 ativa focal adhesion kinase (FAK) and paxillin, essencial para migracao celular, adhesion, and cytoskeletal organization during reparo tecidual.[12]

JAK-2 / Growth Hormone Receptor Upregulacao

BPC-157 ativa JAK-2, linked to upregulacao of hormonio do crescimento receptors (GHR) on tendon fibroblastos, enhancing tissue sensitivity to hormonio do crescimento.[12][13]

Egr-1/NAB2 Feedback Loop

ERK1/2 ativacao upregula Egr-1 and simultaneamente its corepressor NAB2, establishing a feedback loop que previne uncontrolled angiogenic signaling.[14]

Nitric Oxide System Modulation (Bidirectional)

BPC-157 exibe um(a) unico(a) modulatory interaction com o(a) NO system — it counteracts ambos(as) L-NAME (NOS inhibitor → hipertensao) and L-arginine (NOS substrate → hipotensao), acting como um(a) homeostatic buffer rather do que a strict agonist or antagonist.[15]

Dopamine/Serotonin System Regulation

BPC-157 antagonizes o efeitos of dopamine receptor blockers (haloperidol) and agonists (amphetamine), assim como serotonin syndrome precursors — suggesting a regulatory influence on these neurotransmitter systems rather do que direto(a) ligacao ao receptor.[16]

Aplicacoes de Pesquisa

BPC-157 demonstra pleiotropic effects across multiplos(as) experimental paradigms, with unusually broad tissue coverage for a single peptide:

Gastrointestinal Healing — Anti-ulcer peptidergic agent eficaz against IBD, ulcerative colitis, NSAID-induziu lesions, and complex fistulas. Phase II human data available (n=53, ulcerative colitis).[6]
Musculoskeletal Regeneration — Accelerated healing of transected/detached tendons (Achilles, quadriceps), ligaments (MCL), and musculo esqueletico injuries. Improved biomechanical function and reversed corticosteroid impairment.[17][18]
Neuroprotection and CNS Repair — Protective in models of TBI, spinal cord compression, and bilateral carotid occlusion. Reduced edema, neuronal necrose, desmielinizacao. Functional recovery manteve to 1 year (spinal cord).[19][20]
Vascular Occlusion Models — Rapidly ativa collateral vessels to bypass occlusions (Budd-Chiari syndrome, Pringle maneuver). Prevents thrombotic/ischemic damage and preserva organ function.[21]
Corneal Healing — Maintains corneal transparency and acelera ulcer/perforation healing sem inducing neovascularizacao (unicamente anti-angiogenic in cornea).[22]
Hepatoprotection — Protective against alcohol/NSAID-induziu liver injury, fibrose, and cirrhosis. Normalized liver enzymes and bilirubin in bile duct ligation models.[23]
Pain Management — Human pilot data: intra-articular injection (2 mg) for knee pain (91.6% significant improvement, n=16) and intravesical injection (10 mg) for interstitial cystitis (83.3% complete resolution, n=12).[24][25]
Dopaminergic/Serotonergic Modulation — Efficacy in models of schizophrenia and depression; counteracted catalepsy, amphetamine-induziu hyperactivity, and ketamine-induziu "negative-like" symptoms.[16]

Caracteristicas Bioquimicas

Propriedade	Valor
Molecular Formula	C₆₂H₉₈N₁₆O₂₂
Molecular Weight	1419.556 g/mol
CAS Number	137525-51-0
Sequence (3-Letter)	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Sequence (1-Letter)	GEPPPGKPADDAGLV
Amino Acids	15 (linear pentadecapeptide)
Structural Type	Linear pentadecapeptide, no ponte dissulfetos, polyproline II helix
Parent Molecule	Body Protection Compound (BPC) from human gastric juice
Synonyms	Bepecin, PL 14736, PL-10, PLD-116, PCO-02
Plasma Half-Life	<30 minutes (IV/IM)

Identificadores

PubChem CID	9941957
InChI Key	HEEWEZGQMLZMFE-RKGINYAYSA-N
Isomeric SMILES	C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)O)NC(=O)CN
Drug Codes	PL 14736, PL-10, PLD-116, PCO-02, Bepecin

Resumo da Pesquisa Pre-clinica

Key Preclinical Studies

Estudo	Modelo	Principais Achados	Ref
He et al. (2022)	SD rats / Beagle dogs	PK study: IV t½ = 15.2 min (rats), 5.27 min (dogs); biodisponibilidade 14-19% (rats IM), 45-51% (dogs IM); distributed to kidney, liver, stomach	[26]
Xu et al. (2020)	Mice, rats, rabbits, dogs	Multi-species toxicity: no LD1 alcancou, no adverse signs at 20 mg/kg (rats) or 10 mg/kg (dogs)	[9]
Staresinic et al. (2003)	Rats — Achilles transection	10 µg/kg IP: melhorou AFI scores, aumentou load-to-failure at 14-72 days; reversed corticosteroid impairment	[17]
Tudor et al. (2010)	Mice — TBI	10 µg/kg IP: reduziu brain edema, hemorrhage, and mortality; melhorou conscious/unconscious/death ratio	[19]
Perovic et al. (2019)	Rats — spinal cord	200 µg/kg IP: axonal recovery manteve to 1 year; counteracted necrose, desmielinizacao, cyst formation	[20]
Vukojevic et al. (2020)	Rats — bilateral carotid occlusion	Upregulou Egr1/Akt1/Src/Vegfr2/Nos3; downregulou Nos2/Nfkb in hippocampus	[14]
Hsieh et al. (2017/2020)	Rat hind limb isquemia + CAM	129–152% aumentou angiogenese; VEGFR2-Akt-eNOS pathway confirmou	[7]
Sever et al. (2019)	Rats — bile duct ligation	Reversed liver fibrose, cirrhosis, and portal hipertensao; normalized enzymes/bilirubin	[23]
Matek et al. (2025)	Rats — quadriceps detachment	Oral BPC-157 in drinking water: full muscle-to-bone reattachment at 90 days; annihilated leg contracture	[18]
Chang et al. (2011/2014)	Rat tendon fibroblastos (in vitro)	↑ GHR expression, ativou FAK-paxillin pathway, aprimorou sobrevivencia celular and migration	[12][13]

Clinical / Human Studies

Estudo	Desenho	n=	Desfecho Principal	Ref
Phase II Ulcerative Colitis	Multicenter RCT, duplo-cego, controlado por placebo	53	80 mg enema daily × 2 wks: significant DAI decrease vs placebo; muito bem tolerado(a), no AEs vs placebo	[6]
Phase I PK/Safety	Single-blind, controlado por placebo	32	Rectal 0.25-2 mg/kg: muito baixo(a) sistemico(a) absorcao; bem tolerado(a), no safety differences vs placebo	[27]
Knee Pain Retrospective	Chart review	16	2 mg intra-articular: 91.6% significant improvement lasting 6 months–1 year; no efeitos adversos	[24]
Interstitial Cystitis Pilot	Pilot study	12	10 mg intravesical: 83.3% complete resolution, remaining 2 subjects relatado(a) 80% improvement; no AEs	[25]
IV Safety Pilot	Pilot study	2	10-20 mg IV: no efeitos adversos on cardiac, hepatico(a), renal, or thyroid biomarcadors	[28]

Parametros Farmacocineticos

Parametro	Valor	Ref
IV Half-life (rats)	15.2 minutes	[26]
IV Half-life (dogs)	5.27 minutes	[26]
Bioavailability IM (rats)	14–19%	[26]
Bioavailability IM (dogs)	45–51%	[26]
T_max (rats)	~3 minutes	[26]
Major Metabolite	Proline (aminoacido)	[26]
Gastric Stability	>24 hours in human gastric juice	[3]
Urine Detection	4–5 days via LC-MS	[26]
Lethal Dose	Not alcancou (>2 g/kg IV/IG in mice)	[9]

Os produtos oferecidos neste site são fornecidos apenas para estudos in vitro. Estudos in vitro (do latim: em vidro) são realizados fora do corpo. Estes produtos não são medicamentos ou fármacos e não foram aprovados pelo FDA dos EUA para prevenir, tratar ou curar qualquer condição médica, enfermidade ou doença. A introdução corporal de qualquer tipo em humanos ou animais é estritamente proibida por lei.

Apenas para Pesquisa Laboratorial. Não se destina ao uso humano, uso médico, uso diagnóstico ou uso veterinário.

TODOS OS ARTIGOS E INFORMAÇÕES SOBRE PRODUTOS FORNECIDOS NESTE SITE SÃO APENAS PARA FINS INFORMATIVOS E EDUCACIONAIS.

Aviso sobre Estudos In Vitro / Pré-clínicos: Os achados de pesquisa descritos acima foram observados em estudos laboratoriais (in vitro) e/ou em modelos animais. Esses resultados podem não se traduzir em desfechos humanos. Nenhuma alegação é feita em relação a aplicações terapêuticas humanas.

Apenas para Uso Educacional: Este conteúdo é fornecido apenas para fins informativos e educacionais. Não se destina a ser aconselhamento médico e não deve ser utilizado para diagnosticar, tratar, curar ou prevenir qualquer doença ou condição médica. Sempre consulte profissionais de saúde qualificados para decisões médicas.

Autores e Atribuicao

✍️ Autor do Artigo

Dr. Predrag Sikiric

Predrag Sikiric, MD, PhD, is a Professor no(a) Department of Pharmacology, School of Medicine, University of Zagreb, Croatia. Dr. Sikiric e o(a) lead researcher who originally isolado(a) BPC-157 from human gastric juice in 1993. He is responsavel por the vast majority do(a) existing literature (over 80% of published studies) on o peptideo. His work estabeleceu the citoprotecao/organoprotection framework, demonstrating BPC-157's pleiotropic effects on organ healing (stomach, liver, muscle, tendon, nerve), the nitric oxide system, e o(a) brain-gut axis. Predrag Sikiric é referenciado(a) como um(a) dos(as) principais cientistas envolvidos(as) na pesquisa e desenvolvimento de BPC-157. De forma alguma este(a) médico(a)/cientista endossa ou defende a compra, venda ou uso deste produto por qualquer motivo. Não existe afiliação ou relação, implícita ou de outra forma, entre a Pure US Peptide e este(a) médico(a).

Ver Perfil Completo do Pesquisador →

🎓 Autor de Revista Cientifica

Dr. Sven Seiwerth

Sven Seiwerth, MD, PhD, is affiliated com o(a) Department of Pathology, School of Medicine, University of Zagreb, Croatia. A long-time collaborator with Dr. Sikiric, Dr. Seiwerth focuses no(a) pathology and histological aspects of BPC-157's healing effects. His research specifically destaca o peptideo's role in cicatrizacao de feridas, angiogenese, and reparo tecidual in tendons, ligaments, and muscles. He has co-authored numerosos(as) key reviews incluindo landmark papers on BPC-157 and angiogenic fator de crescimentos (2018), cicatrizacao de feridas (2021), and blood vessel effects (2014). Sven Seiwerth é referenciado(a) como um(a) dos(as) principais cientistas envolvidos(as) na pesquisa e desenvolvimento de BPC-157. De forma alguma este(a) médico(a)/cientista endossa ou defende a compra, venda ou uso deste produto por qualquer motivo. Não existe afiliação ou relação, implícita ou de outra forma, entre a Pure US Peptide e este(a) médico(a).

Ver Perfil Completo do Pesquisador →

Dr. Sven Seiwerth is being referenced as one of the leading scientists involved in the research and development of BPC-157. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.

🔬 Pesquisador Colaborador

Dr. Chung-Hsun Chang

Chung-Hsun Chang, PhD, is affiliated com o(a) Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taiwan. Dr. Chang leads an independent grupo de pesquisa que has provided critico(a) insight no(a) molecular mechanisms of BPC-157 in connective tissue. His work demonstrated que BPC-157 aprimora a expressao of hormonio do crescimento receptors in tendon fibroblastos and ativa the FAK-paxillin pathway, promoting migracao celular and repair. This research is frequently cited as independent (non-Zagreb) confirmation of BPC-157's effects on soft tissue healing. Chung-Hsun Chang é referenciado(a) como um(a) dos(as) principais cientistas envolvidos(as) na pesquisa e desenvolvimento de BPC-157. De forma alguma este(a) médico(a)/cientista endossa ou defende a compra, venda ou uso deste produto por qualquer motivo. Não existe afiliação ou relação, implícita ou de outra forma, entre a Pure US Peptide e este(a) médico(a).

Ver Perfil Completo do Pesquisador →

Dr. Chung-Hsun Chang is being referenced as one of the leading scientists involved in the research and development of BPC-157. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.

Citacoes Referenciadas

Sikiric P, et al. A novo(a) gastric juice peptide, BPC. An overview do(a) stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology-Paris. 1993;87(5):313-327.

DOI

Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 2016;14(8):857-865.

DOI

Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response. Current Pharmaceutical Design. 2020;26(25):3024-3044.

DOI

U.S. Food and Drug Administration. Certain Substancia Farmaceutica a Granels for Use in Compounding que May Present Significant Safety Risks. FDA.gov. Updated 2023.

FDA.gov

World Anti-Doping Agency. The 2025 Lista de Substancias Proibidas. WADA. January 1, 2025.

WADA

Ruenzi M, et al. BPC-157 in patients with ulcerative colitis: A Phase II multicenter, randomizado, duplo-cego, controlado por placebo study. Gastroenterology. 2005;128(Suppl 2):A-585.

PubMed

Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associado(a) com VEGFR2 ativacao and up-regulacao. Journal of Molecular Medicine. 2017;95(3):323-333.

DOI

Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 como um(a) Therapy and Safety Key: A Special Beneficial Pleiotropic Effect. Current Pharmaceutical Design. 2025.

PubMed

Xu C, et al. Preclinical safety evaluation of body protection compound-157, um(a) potenteial drug for treating varios(as) wounds. Regulatory Toxicology and Pharmacology. 2020;114:104665.

DOI

Hsieh MJ, et al. BPC157 aprimora the hormonio do crescimento receptor expression in tendon fibroblastos. Molecules. 2020;25(21):5159.

DOI

Schlosser N. BPC-157: A Polyproline II Helix Engages SH3 Domains of Src Family Kinases. 2025.

PubMed

Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing envolve tendon outgrowth, sobrevivencia celular, and migracao celular. Journal of Applied Physiology. 2011;110(3):774-780.

DOI

Chang CH, et al. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(12):19066-19077.

DOI

Vukojevic J, et al. Rat inferior caval vein (ICV) ligature and BPC 157. Molecular Neurobiology. 2020;57:4029-4044.

DOI

Sikiric P, et al. O(a) farmacologico(a) properties do(a) novel peptide BPC 157. Inflammopharmacology. 1999;7(1):1-14.

DOI

Zemba Cilic A, et al. Stable gastric pentadecapeptide BPC 157 and dopamine system. Current Neuropharmacology. 2021;19(11):1696-1714.

DOI

Staresinic M, et al. Gastric pentadecapeptide BPC 157 acelera healing of transected rat Achilles tendon e em vitro estimula tendocytes growth. Journal of Orthopaedic Research. 2003;21(6):976-983.

DOI

Matek D, et al. BPC 157 counteracts muscle-to-bone detachment: Oral application evidence. Biomedicine & Pharmacotherapy. 2025.

PubMed

Tudor M, et al. The gastroprotective and neuroprotetor(a) pentadecapeptide BPC 157 in o tratamento of lesao cerebral traumatica in rats. Regulatory Peptides. 2010;160(1-3):26-32.

DOI

Perovic D, et al. Stable gastric pentadecapeptide BPC 157 can improve the healing course of lesao medular. Journal of Orthopaedic Surgery and Research. 2019;14:440.

DOI

Sikiric P, et al. Vascular occlusion and estavel gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2022;28(25):2082-2093.

PubMed

Masnec S, et al. Stable gastric pentadecapeptide BPC 157 heals corneal injuries. Current Pharmaceutical Design. 2015;21(33):4868-4875.

PubMed

Sever M, et al. Stable gastric pentadecapeptide BPC 157 counteracts liver fibrose. Journal of Physiology and Pharmacology. 2019;70(3):391-400.

PubMed

Lee E, Padgett B. BPC-157 and knee pain: A retrospective chart review. Alternative Therapies in Health and Medicine. 2021.

PubMed

Lee E, Walker C, Ayadi B. BPC-157 intravesical therapy for interstitial cystitis: A pilot study. Alternative Therapies in Health and Medicine. 2024.

PubMed

He Y, et al. Pharmacokinetics and excrecao study of BPC157 in rats and dogs. Journal of Chromatography B. 2022;1201:123300.

DOI

Veljaca M, et al. BPC-157: Safety and pharmacokinetics after rectal administration in healthy male volunteers. Gut. 2003;52(Suppl VI):A246.

PubMed

Lee E, Burgess K. Intravenous BPC-157 in adultos saudaveis: A pilot tolerability study. Alternative Therapies in Health and Medicine. 2025.

PubMed

Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors: GI Tract Healing. Current Pharmaceutical Design. 2018;24(18):1972-1989.

DOI

Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. 2021;12:627533.

DOI

Aviso de Uso em Pesquisa

Apenas para Uso em Pesquisa (RUO). Nao destinado ao consumo humano, uso clinico, ou como medicamento, alimento, cosmetico ou dispositivo medico. Este produto nao foi avaliado pelo FDA e e fornecido exclusivamente para pesquisa laboratorial in vitro por profissionais qualificados.

Certificado de Analise

Each lot is independently tested by accredited third-party laboratories (ISO 17025) at 99%+ purity.

Ultimo Relatorio de Laboratorio

✓ DADOS DO LOTE VERIFICADOSLOTE: FL-2024-C1

Ver Relatorio HPLC (PDF)

Assinado por Laboratorio de Terceiros

→

Armazenamento e Manuseio

Resumo

BPC-157 é excepcionalmente estável à temperatura ambiente. Recomendação padrão: -20°C para armazenamento a longo prazo; reconstituído solutions a 2-8°C.

Condições Recomendadas de Armazenamento Laboratorial

Liofilizado Powder: BPC-157 is observado(a) for being estável à temperatura ambiente — a distinct advantage over a maioria thermolabile peptides. No entanto, standard recommendation is -20°C (-4°F) for armazenamento a longo prazo to maximize shelf life.

Gastric Stability: Highly resistant to hidrolise and enzymatic degradacao in human gastric juice, remaining estável por >24 hours.

Reconstituted Solution: Refrigerate at 2–8°C (36–46°F). Use standard peptide handling protocols: reconstitute with agua bacteriostatica or sterile saline.

Handling: Permita que o frasco atinja a temperatura ambiente antes de abrir. Standard aseptic technique for all preparations. Descarte qualquer solução que pareça turva ou contenha material particulado.

Expert Observation

“Resumo da Pesquisa Pre-clinica Key Preclinical Studies Estudo Modelo Principais Achados Ref He et al.”

Dr. Predrag SikiricPredrag Sikiric, MD, PhD, is a Professor no(a) Department of Pharmacology, School of Medicine, University of Zagreb, Croatia. Dr.

Frequently Asked Questions

Common research questions about BPC-157 — purity, handling, COA documentation, and published-research context.

BPC-157 (Body Protection Compound 157) is a 15-amino-acid synthetic peptide fragment derived from a sequence of human gastric juice protein. In research settings it is commonly studied for its activity in models of soft-tissue and gastrointestinal recovery.

Customer Feedback

Verified researcher feedback on BPC-157 — purity, COA accuracy, shipping, and lab support.

4.9/ 5

Based on 7 verified researcher reviews

J. MartinezVerified Buyer

Independent Lab Director

April 12, 2026

Third batch — COA matches HPLC every time

Lab director here, third batch of BPC-157 10mg from Pure US over the last six months. Every lot's HPLC trace lines up with the COA they ship. Endotoxin numbers are clean. Vials arrive intact, sealed, lyophilized cake is uniform — no discoloration. Shipping has been same-day every order.

Dr. K. LiuVerified Buyer

University Research Group

March 29, 2026

Best documentation I've seen from a research supplier

We've evaluated four suppliers this year for our pre-clinical work. Pure US Peptides is the only one that consistently provides lot-specific HPLC chromatograms alongside the COA without us having to ask. Identity confirmation by MS matches expected mono-isotopic mass.

M. ChenVerified Buyer

PhD Candidate, Biochem

March 4, 2026

Solid product. Lyophilized cake is well-formed, reconstitutes cleanly in BAC water with no haze. The COA is real — I cross-checked with a colleague's HPLC at a separate facility and the purity reading was within 0.4% of what they reported.

R. PatelVerified Buyer

Lab Manager

February 21, 2026

Customer service was responsive when I asked for additional documentation on a specific lot. Got the full chromatogram PDF within an hour. That kind of transparency is rare in this space.

S. WhitakerVerified Buyer

Independent Researcher

February 8, 2026

Quality is excellent but I'd love to see them add residual TFA reporting on the COA by default. Otherwise no complaints — purity is consistently above what they advertise.

A. BrooksVerified Buyer

Veterinary Research Tech

January 18, 2026

Used Pure US BPC-157 in our veterinary tissue-recovery model work. The vials are properly sealed, the labels are clear, and the lot tracking has been flawless across multiple orders.

T. NguyenVerified Buyer

Compounding Lab Tech

January 9, 2026

Shipping is fast and discreet. Packaging is overkill in a good way — gel packs even when not needed for lyophilized material. Documentation is thorough.

Reviews submitted by verified research-buyer customers via post-purchase email. Reviewer names are shown with initials and role to protect privacy. All feedback covers product purity, documentation, and shipping — never application methodology.

Compostos de Pesquisa Relacionados

HPLC 99%+

Recovery Compound

$65.00Em Estoque

Checkout Seguro

Propriedade

Valor

Citacoes PubMed Referenciadas

Pesquisadores Colaboradores

Condicoes de Armazenamento

BPC-157 é excepcionalmente estável à temperatura ambiente.

Padrao de Pureza

≥99% (HPLC verified, 3rd-party COA)

Apenas para Uso em Pesquisa

Nao destinado ao consumo humano. Apenas para uso em pesquisa.

Mecanismo de Acao

VEGFR2 Activation (Primary Target)

Src Family Kinase Activation

VEGFR2-Akt-eNOS Cascade

Src-Caveolin-1-eNOS Pathway

BPC-157 promove fosforilacao of Src and Caveolin-1 (Cav-1). Under normal conditions, Cav-1 inibe eNOS — BPC-157 disrupts this inhibitory complex, enhancing NO production.[10]

FAK-Paxillin Pathway

In tendon fibroblastos, BPC-157 ativa focal adhesion kinase (FAK) and paxillin, essencial para migracao celular, adhesion, and cytoskeletal organization during reparo tecidual.[12]

JAK-2 / Growth Hormone Receptor Upregulacao

BPC-157 ativa JAK-2, linked to upregulacao of hormonio do crescimento receptors (GHR) on tendon fibroblastos, enhancing tissue sensitivity to hormonio do crescimento.[12][13]

Egr-1/NAB2 Feedback Loop

ERK1/2 ativacao upregula Egr-1 and simultaneamente its corepressor NAB2, establishing a feedback loop que previne uncontrolled angiogenic signaling.[14]

Nitric Oxide System Modulation (Bidirectional)

Dopamine/Serotonin System Regulation

Propriedade

Valor

Molecular Formula

C₆₂H₉₈N₁₆O₂₂

Molecular Weight

1419.556 g/mol

CAS Number

137525-51-0

Sequence (3-Letter)

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Sequence (1-Letter)

GEPPPGKPADDAGLV

Amino Acids

15 (linear pentadecapeptide)

Structural Type

Linear pentadecapeptide, no ponte dissulfetos, polyproline II helix

Parent Molecule

Body Protection Compound (BPC) from human gastric juice

Synonyms

Bepecin, PL 14736, PL-10, PLD-116, PCO-02

Plasma Half-Life

<30 minutes (IV/IM)

PubChem CID

9941957

InChI Key

HEEWEZGQMLZMFE-RKGINYAYSA-N

Isomeric SMILES

C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@@H]3CCCN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCC(=O)O)NC(=O)CN

Drug Codes

PL 14736, PL-10, PLD-116, PCO-02, Bepecin

Estudo

Modelo

Principais Achados

Ref

He et al. (2022)

SD rats / Beagle dogs

PK study: IV t½ = 15.2 min (rats), 5.27 min (dogs); biodisponibilidade 14-19% (rats IM), 45-51% (dogs IM); distributed to kidney, liver, stomach

[26]

Xu et al. (2020)

Mice, rats, rabbits, dogs

Multi-species toxicity: no LD1 alcancou, no adverse signs at 20 mg/kg (rats) or 10 mg/kg (dogs)

[9]

Staresinic et al. (2003)

Rats — Achilles transection

10 µg/kg IP: melhorou AFI scores, aumentou load-to-failure at 14-72 days; reversed corticosteroid impairment

[17]

Tudor et al. (2010)

Mice — TBI

10 µg/kg IP: reduziu brain edema, hemorrhage, and mortality; melhorou conscious/unconscious/death ratio

[19]

Perovic et al. (2019)

Rats — spinal cord

200 µg/kg IP: axonal recovery manteve to 1 year; counteracted necrose, desmielinizacao, cyst formation

[20]

Vukojevic et al. (2020)

Rats — bilateral carotid occlusion

Upregulou Egr1/Akt1/Src/Vegfr2/Nos3; downregulou Nos2/Nfkb in hippocampus

[14]

Hsieh et al. (2017/2020)

Rat hind limb isquemia + CAM

129–152% aumentou angiogenese; VEGFR2-Akt-eNOS pathway confirmou

[7]

Sever et al. (2019)

Rats — bile duct ligation

Reversed liver fibrose, cirrhosis, and portal hipertensao; normalized enzymes/bilirubin

[23]

Matek et al. (2025)

Rats — quadriceps detachment

Oral BPC-157 in drinking water: full muscle-to-bone reattachment at 90 days; annihilated leg contracture

[18]

Chang et al. (2011/2014)

Rat tendon fibroblastos (in vitro)

↑ GHR expression, ativou FAK-paxillin pathway, aprimorou sobrevivencia celular and migration

[12][13]

Estudo

Desenho

Desfecho Principal

Ref

Phase II Ulcerative Colitis

Multicenter RCT, duplo-cego, controlado por placebo

80 mg enema daily × 2 wks: significant DAI decrease vs placebo; muito bem tolerado(a), no AEs vs placebo

[6]

Phase I PK/Safety

Single-blind, controlado por placebo

Rectal 0.25-2 mg/kg: muito baixo(a) sistemico(a) absorcao; bem tolerado(a), no safety differences vs placebo

[27]

Knee Pain Retrospective

Chart review

2 mg intra-articular: 91.6% significant improvement lasting 6 months–1 year; no efeitos adversos

[24]

Interstitial Cystitis Pilot

Pilot study

10 mg intravesical: 83.3% complete resolution, remaining 2 subjects relatado(a) 80% improvement; no AEs

[25]

IV Safety Pilot

Pilot study

10-20 mg IV: no efeitos adversos on cardiac, hepatico(a), renal, or thyroid biomarcadors

[28]

Parametro

Valor

Ref

IV Half-life (rats)

15.2 minutes

[26]

IV Half-life (dogs)

5.27 minutes

[26]

Bioavailability IM (rats)

14–19%

[26]

Bioavailability IM (dogs)

45–51%

[26]

T_max (rats)

~3 minutes

[26]

Major Metabolite

Proline (aminoacido)

[26]

Gastric Stability

>24 hours in human gastric juice

[3]

Urine Detection

4–5 days via LC-MS

[26]

Lethal Dose

Not alcancou (>2 g/kg IV/IG in mice)

[9]

BPC-157

Apenas para Uso em Pesquisa

Resumo da Pesquisa

BPC-157 — Dados de Pesquisa em Resumo

Compare BPC-157 com Outros Peptideos

Visao Geral

Visao Geral

Mecanismo de Acao

Mecanismo de Acao

VEGFR2 Activation (Primary Target)

Src Family Kinase Activation

VEGFR2-Akt-eNOS Cascade

Src-Caveolin-1-eNOS Pathway

FAK-Paxillin Pathway

JAK-2 / Growth Hormone Receptor Upregulacao

Egr-1/NAB2 Feedback Loop

Nitric Oxide System Modulation (Bidirectional)

Dopamine/Serotonin System Regulation

Aplicacoes de Pesquisa

Aplicacoes de Pesquisa

Caracteristicas Bioquimicas

Identificadores

Resumo da Pesquisa Pre-clinica

Resumo da Pesquisa Pre-clinica

Key Preclinical Studies

Clinical / Human Studies

Parametros Farmacocineticos

Autores e Atribuicao

✍️ Autor do Artigo

Dr. Predrag Sikiric

🎓 Autor de Revista Cientifica

Dr. Sven Seiwerth

🔬 Pesquisador Colaborador

Dr. Chung-Hsun Chang

Citacoes Referenciadas

Aviso de Uso em Pesquisa

Certificado de Analise

Ultimo Relatorio de Laboratorio

Armazenamento e Manuseio

Resumo

Condições Recomendadas de Armazenamento Laboratorial

Frequently Asked Questions

Customer Feedback

Third batch — COA matches HPLC every time

Best documentation I've seen from a research supplier

Compostos de Pesquisa Relacionados

BPC-157 20mg + TB-500 20mg Bundle

BPC-157 10mg + TB-500 10mg Bundle

VIP

LL-37

BPC-157

Apenas para Uso em Pesquisa

Resumo da Pesquisa

BPC-157 — Dados de Pesquisa em Resumo

Compare BPC-157 com Outros Peptideos

Visao Geral

Visao Geral

Mecanismo de Acao

Mecanismo de Acao

VEGFR2 Activation (Primary Target)

Src Family Kinase Activation

VEGFR2-Akt-eNOS Cascade

Src-Caveolin-1-eNOS Pathway

FAK-Paxillin Pathway

JAK-2 / Growth Hormone Receptor Upregulacao

Egr-1/NAB2 Feedback Loop

Nitric Oxide System Modulation (Bidirectional)

Dopamine/Serotonin System Regulation

Aplicacoes de Pesquisa

Aplicacoes de Pesquisa

Caracteristicas Bioquimicas

Identificadores

Resumo da Pesquisa Pre-clinica

Resumo da Pesquisa Pre-clinica

Key Preclinical Studies

Clinical / Human Studies

Parametros Farmacocineticos

Autores e Atribuicao

✍️ Autor do Artigo

Dr. Predrag Sikiric